Clinical Toxicology Testing: A Guide For Laboratory Professionals, 2nd edition - PUB227
PUB227_LARGE_IMAGE

Clinical Toxicology Testing: A Guide for Laboratory Professionals, Second Edition

Barbarajean Magnani, PhD, MD, FCAP
Tai C. Kwong, PhD, DABCC, FACB
Gwendolyn A. McMillin, MD, FCAP
Alan H.B. Wu, PhD, DABCC, FACB

Clinical Toxicology Testing is a practical guide, written for pathologists, to directing hospital toxicology laboratory operations. This new edition builds upon the contents of the first edition, with expanded sections on testing in the clinical setting, methodologies, and more user‐friendly information on specific analytes. It provides the reader with a comprehensive view of what is needed‐and expected‐when offering a clinical toxicology service.

Contents include

  • Toxicology testing supporting the emergency department, hospital autopsies, and pain management services, including chronic opioid therapy
  • Pediatric toxicology testing, workplace drug testing, and regulatory issues
  • Toxicokinetics and methodologies, with new and expanded information on laboratory-developed tests, screening assays, targeted tests, and use of oral fluid and alternative matricies for testing
  • Specific analytes, including ethanol and non-ethanol volatiles, cannabis, club drugs, cocaine, amphetamines, barbiturates, benzodiazepines, opiates/opioids, novel psychoactive substances, OTC analgesics, and lead and other metals and toxicants
  • Appendices on urine and serum screens, therapeutic drug monitoring, FAQs, and proficiency testing

Contents (PDF, 56 KB)
Sample pages (PDF, 5246 KB)

Softcover; 376 pages; 2020
ISBN: 978-194109650-5





Non-Member Price:   $100.00  
 
Member Price:  $80.00   


Practical guide to directing hospital toxicology laboratory operations. New edition contents: Toxicology testing in the clinical setting, including new chapters on pediatric testing and chronic opioid therapy; Toxicokinetics and methodologies, with new and expanded information on laboratory-developed tests, screening assays, targeted tests, and oral fluids and alternative matricies; Specific analytes, including novel psychoactive substances and the use of medical cannabis; Appendices on urine and serum screens, therapeutic drug monitoring, and proficiency testing.